What is STOK's market cap?

$1.77B, based on the Nov 4 close of $27.45.

Does Stoke Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of STOK is sold short?

10.3M shares, 18.9% of float, as of Oct 15, 2026.

What sector is STOK in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · STOKHealthcarePharmaceuticals

Stoke Therapeutics, Inc. Common Stock (STOK)

$27.45+1.70%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$27.44▲ 8.29% in range

Nov 4, 2025Low $22.37 · High $38.35Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Stoke Therapeutics closed at $27.45 on Nov 4, up 1.70%, 28.4% below its 52-week closing high. Volume of 1.2M shares was 0.93× its 20-day average (close to normal).

Split-adjusted performance: +12.6% over one month, -17.5% over six months, +5.2% over one year.

In the quarter ended Sep 30, 2026, revenue was $11.26M, up 5.9% from a year earlier, with a net margin of -654.3%.

Short interest was 10.3M shares at the Oct 15 settlement, down 10.9% from the prior report (18.9% of float, 12.3 days to cover).

Market cap$1.77B64.5M shares

Revenue · quarter$11.3M+5.9% YoY

Diluted EPS$-1.08—

P/E · TTM—P/S 62.8×

Net margin-654.3%Gross 100.0%

Dividend yieldNone

52-week range22.37 – 38.35−28.4% from high

Volume1.2M0.93× 20-day avg

Volatility · 60d47.9%Annualised

Short % of float18.9%12.3 days to cover

Net cash$319.2MCash $319.2M

Next earnings—Not scheduled

Split-adjusted performance

1W +3.9%1M +12.6%3M −14.0%6M −17.5%YTD −13.5%1Y +5.2%3Y +668.9%5Y +13.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum59

Revenue growth49

Net margin26

Value (low P/E)—

Size79

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short10.3M−10.9% vs prior

Days to cover12.3Settled Oct 15

% of float18.9%

Short vol. 10d71.2%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
STOKStoke Therapeutics	$27.45	+1.70%	−17.5%	+5.9%	−654.3%	—	$1.77B
NRIXNurix Therapeutics	$15.95	−38.23%	−5.5%	+8426.3%	81.7%	5.9	$1.74B	Compare
PGENPrecigen	$5.06	−3.71%	+14.9%	+6322.7%	36.5%	—	$1.81B	Compare
BRVEBraveheart Bio	$20.11	−6.01%	—	—	—	—	$1.81B	Compare
GENBGenerate Biomedicines	$14.16	+2.24%	—	—	−1065.2%	—	$1.82B	Compare
SLSSELLAS Life Sciences Group	$9.14	+3.04%	+77.5%	—	—	—	$1.85B	Compare
RAREUltragenyx Pharmaceutical	$17.16	+3.19%	−33.8%	+28.1%	−43.0%	—	$1.69B	Compare
ZBIOZenas BioPharma	$28.46	+0.28%	+36.6%	—	−11145.6%	—	$1.85B	Compare
AGIOAgios Pharmaceuticals	$31.38	+0.58%	+16.3%	+259.3%	−225.1%	—	$1.87B	Compare

News about Stoke Therapeutics

All news →

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 6d ago▼ Negative

Quick answers

What does Stoke Therapeutics do?: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively.
What is STOK's market cap?: $1.77B, based on the Nov 4 close of $27.45.
Does Stoke Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of STOK is sold short?: 10.3M shares, 18.9% of float, as of Oct 15, 2026.
What sector is STOK in?: Healthcare, in the Pharmaceuticals industry.

About Stoke Therapeutics

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

HQ: Bedford, MA170 employeesListed Jun 19, 2019stoketherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology